Escobar Supports Nixing $40B FCA Suit, Celgene Says
A trio of rulings based on the U.S. Supreme Court's landmark Escobar decision in June show the government's continued reimbursement for cancer drugs Thalomid and Revlimid render a $40 billion False...To view the full article, register now.
Already a subscriber? Click here to view full article